4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Irritable Bowel Syndrome by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 236 ongoing clinical trials involving Irritable Bowel Syndrome
Of the 236 trials,99 trials are in Phase II
Furthermore, 67 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Irritable Bowel Syndrome by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Irritable Bowel Syndrome, a Gastrointestinal condition. The largest number of ongoing clinical trials for Irritable Bowel Syndrome is conducted in the Asia-Pacific region. Europe and North America are among some of the other prominent regions engaged in Irritable Bowel Syndrome-related drug trials.

Allergan Ltd: The leading ongoing Irritable Bowel Syndrome related clinical trial sponsor

Allergan Ltd is the top sponsor for Irritable Bowel Syndrome-related ongoing clinical trials.

Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing Hospital of Traditional Chinese Medicine, Academic Medical Center, University of Michigan, and Tohoku University Hospital are among other notable clinical trial sponsors involved in Irritable Bowel Syndrome. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Irritable Bowel Syndrome

Rifaximin (Xifaxan/ Normix/ Spiraxin/ Normiks/ Refero/ Targaxan/ Tixteller/ Zaxine/ Faxinorm/ Xifaxanta/ Redactiv/ Tixtar/ Rifacol/ Rifxima), Linaclotide (Linzess, Constella), and Lubiprostone (Amitiza) are among the key marketed drugs involving Irritable Bowel Syndrome.

Rifaximin (Xifaxan/ Normix/ Spiraxin/ Normiks/ Refero/ Targaxan/ Tixteller/ Zaxine/ Faxinorm/ Xifaxanta/ Redactiv/ Tixtar/ Rifacol/ Rifxima) is a non-aminoglycoside semi-synthetic antibiotic acts as anti-bacterial agent. It functions via DNA Directed RNA Polymerase (POLR2 or EC 2.7.7.6) Inhibitor mechanism of action. It is formulated as tablets, film coated tablets and granules for oral route of administration and ointment and cream for topical application. Rafle is indicated for the treatment of patients with travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli and reduction in risk of overt hepatic encephalopathy. Rifaximin was first approved in 1985 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Salix Pharmaceuticals Inc.

Linaclotide (Linzess, Constella) is an anti-constipation agent. It functions via Heat Stable Enterotoxin Receptor Agonist mechanism of action. It is formulated as hard gelatin capsules and tablets for oral route of administration. Linaclotide is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) when dietary fibre, laxatives and stool softeners have not been sufficient and with adequate constipation minimisation dietary support. Linaclotide was first approved in 2012 and is marketed globally including in the US, the UK, Australia, France, Germany, and China, by Allergan Sales LLC.